Get the Stockscreener App
16.38
1.92%
-0.25
Stevanato Group Spa stock is traded at $16.38, with a volume of 135.98K.
It is down -1.92% in the last 24 hours and down -9.34% over the past month.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
See More
Previous Close:
$16.63
Open:
$16.98
24h Volume:
135.98K
Relative Volume:
0.26
Market Cap:
$4.46B
Revenue:
$1.40B
Net Income/Loss:
$164.00M
P/E Ratio:
27.26
EPS:
0.6009
Net Cash Flow:
$-11.09M
1W Performance:
-9.89%
1M Performance:
-9.34%
6M Performance:
-21.92%
1Y Performance:
-32.85%
1-Day Range:
$16.27
$17.17
1-Week Range:
$16.28
$18.46
52-Week Range:
$12.89
$28.00
Stevanato Group Spa Stock (STVN) Company Profile
Name
Stevanato Group Spa
Sector
Industry
Phone
-
Address
-
Compare STVN vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STVN
Stevanato Group Spa
|
16.32 | 4.54B | 1.40B | 164.00M | -11.09M | 0.6009 |
ISRG
Intuitive Surgical Inc
|
417.99 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
146.07 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.28 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.81 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
194.13 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Stevanato Group Spa Stock (STVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Dec-03-24 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-22-24 | Initiated | Exane BNP Paribas | Outperform |
| Nov-01-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-26-23 | Initiated | Stephens | Overweight |
| Sep-19-23 | Initiated | CJS Securities | Market Outperform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-10-21 | Initiated | BofA Securities | Buy |
| Aug-10-21 | Initiated | Citigroup | Buy |
| Aug-10-21 | Initiated | Jefferies | Buy |
| Aug-10-21 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-10-21 | Initiated | Morgan Stanley | Overweight |
| Aug-10-21 | Initiated | Wells Fargo | Overweight |
View All
Stevanato Group Spa Stock (STVN) Latest News
Stevanato Group S.p.A. (STVN) Stock Analysis: Exploring a 42.79% Potential Upside in the Medical Instruments Sector - DirectorsTalk Interviews
Stevanato Group (STVN) Stock Valuation Check After Recent Share Price Weakness - Yahoo Finance
Sustainable Pharmaceutical Packaging Market to Reach USD 270.4 Billion by 2031, Wissen Research - Moomoo
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now? - Insider Monkey
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside - Seeking Alpha
Stevanato Group launches pen injector for diabetes drugs By Investing.com - Investing.com Nigeria
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now - The Motley Fool
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies - Manufacturing Chemist
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneo - GuruFocus
Stevanato Group (STVN) Q1 2026 Earnings: EPS Beats Estimates Amid Quiet Revenue DisclosureShort-Term Outlook - newsline.com
Stevanato Group Launches Deora Pen Injector for Diabetes and Weight Management Therapies - World Business Outlook
Stevanato Group launches pen injector platform targeting GLP-1, obesity drug market - Medical Economics
Stevanato Group Introduces New Proprietary Pen Injector Platform - Contract Pharma
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management - Stevanato Group S.p.A. (STVN)
Stevanato Group launches pen injector for diabetes drugs - Investing.com UK
Stevanato Group S.p.A. (STVN): Analyst Consensus Highlights 32.12% Potential Upside - DirectorsTalk Interviews
Stevanato Group S.p.A (STVN) Q4 2023 Earnings Call Transcript - MLQ.ai
(STVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Stevanato Group (STVN) Holds Steady Near Support as Market Weighs FundamentalsBollinger Band - newsline.com
[6-K] Stevanato Group S.p.A. Current Report (Foreign Issuer) | STVN SEC FilingForm 6-K - Stock Titan
Stevanato faces earnings test on high-value product mix shift By Investing.com - Investing.com UK
Stevanato faces earnings test on high-value product mix shift - Investing.com
Stevanato Group’s Quiet Revolution: Governance for a Modern Era - BriefGlance
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders’ Meeting - Stevanato Group S.p.A. (STVN)
Implied Volatility Surging for Stevanato Stock Options - Yahoo Finance
STVN Assumes Outperform by Wolfe Research -- Price Target Announ - GuruFocus
Wolfe Research initiates Stevanato stock with Outperform rating By Investing.com - Investing.com India
Wolfe Research initiates Stevanato stock with Outperform rating - Investing.com
Stevanato Group S.p.A. (STVN) Stock Analysis: An Under-the-Radar Healthcare Gem with 33% Upside Potential - DirectorsTalk Interviews
Stevanato’s GLP-1 Tailwinds Meet A Guidance Reality Check - Finimize
Stevanato Group (STVN) Holds Steady Near $18.66 as Consolidation BuildsHigh Volume Node - newsline.com
Stevanato Group (STVN) Q1 2026 Earnings: EPS Beat Drives Shares Higher Despite Revenue UncertaintyEarnings Decline Risk - newsline.com
Stevanato Group SpA (N: STVN) Share Price, STVN Stock News, STVN Share Price & Updates - Kalkine
Stevanato Group (STVN) Edges Lower Amid Light Trading, Holds Near Key SupportVolume Spike Alerts - newsline.com
(STVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Stevanato Group S.p.A. (STVN) Stock Analysis: Unpacking a Potential 37.89% Upside in the Healthcare Sector - DirectorsTalk Interviews
Stevanato maintains 2026 guidance of €1.260B-€1.290B revenue as it targets RTU cartridge production in early 2027 - MSN
Stevanato Group's Valuation Adjustment Signals Improved Financial Health and Market Position - Markets Mojo
Top Stevanato Group (STVN) Competitors 2026 - MarketBeat
Stevanato Group Earnings Call Highlights Growth and Strain - The Globe and Mail
Stevanato Group Posts Strong Q1 2026 Growth and Accelerates Cartridge Capacity Expansion - TipRanks
Stevanato Group S.p.A. (STVN) Stock Analysis: A 38% Potential Upside Draws Investor Attention - DirectorsTalk Interviews
Liquidity Mapping Around (STVN) Price Events - Stock Traders Daily
Stevanato Group S.p.A. Ordinary Shares (NY: STVN - The Chronicle-Journal
Stevanato Group (NYSE: STVN) posts Q1 2026 growth and reaffirms 2026 outlook - Stock Titan
Baron entities (STVN) report 2.5M shares, 5.03% beneficial ownership - Stock Titan
Stevanato Group Spa Stock (STVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):